Researchers From Poland Find That Common Heart Drugs Could Help Fight Colon Cancer
Nikhil Prasad Fact checked by:Thailand Medical News Team Aug 06, 2026 37 minutes ago
Researchers Explore How Beta-Blockers Could Become New Weapons Against Colorectal Cancer
A growing body of scientific evidence suggests that a group of inexpensive heart medications known as beta-blockers could one day play an important role in the fight against colorectal cancer. Researchers from the Department of Molecular Biology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Poland, and the Silesia LabMed: Centre for Research and Implementation, Medical University of Silesia, Katowice, Poland, have reviewed the latest evidence showing how these drugs may slow cancer growth and improve the effectiveness of existing cancer treatments.
Researchers find that widely used beta-blockers may one day become affordable add-on treatments for colorectal cancer
by blocking several tumor-promoting pathways
Colorectal cancer is one of the world's deadliest cancers despite major advances in surgery, chemotherapy, targeted therapies, and immunotherapy. Many patients eventually develop treatment resistance, creating an urgent need for new approaches that are safe, affordable, and effective.
Stress May Be Fueling Cancer Growth
The researchers explain that long-term psychological stress can activate the body's "fight-or-flight" system, causing increased release of the hormones adrenaline and noradrenaline. These hormones stimulate beta-adrenergic receptors found not only in healthy tissues but also on colorectal cancer cells and within the tumor's surrounding environment.
Once activated, these receptors trigger a chain of biological events that encourage cancer cells to multiply, survive longer, spread to other organs, form new blood vessels, and evade the body's immune defenses. Because beta-blockers prevent these receptors from being activated, scientists believe they may interrupt several processes that tumors rely on to grow.
A Low-Cost Drug with Multiple Possible Benefits
Beta-blockers have been prescribed for decades to treat high blood pressure, heart rhythm disorders, and other cardiovascular conditions. Among them, propranolol has attracted the greatest attention because it blocks both major beta receptors involved in cancer biology.
This
Thailand Medical News report highlights that laboratory studies suggest propranolol can reduce cancer cell growth, decrease blood vessel formation that feeds tumors, suppress cancer cell migration, and increase cancer cell death. Researchers also found evidence that beta-blockers may help reduce inflammation within tumors while improving immune responses against cancer.
Blocking Several Cancer Pathways at Once
One of the most promising findings is that beta-blockers appear to interfere with several important molecular pathways instead of targeting only one.
The review describes how blocking beta-adrenergic signaling may reduce activity in the cAMP/PKA/CREB pathway, which normally promotes cancer cell survival and stimulates genes linked to uncontrol
led growth. The drugs may also weaken the PI3K/AKT/mTOR pathway, a major driver of tumor survival and resistance to treatment, while reducing activity in the RAS/RAF/MEK/ERK pathway that helps cancer cells multiply rapidly.
By disrupting several pathways simultaneously, beta-blockers may slow tumor progression, reduce the chances of metastasis, improve sensitivity to chemotherapy, targeted treatments, and possibly immunotherapy.
More Research Is Still Needed
Although the laboratory and observational findings are encouraging, the researchers stress that important questions remain unanswered. Most of the available evidence comes from experimental studies and retrospective clinical observations rather than large randomized clinical trials.
Scientists also believe future studies should identify which patients are most likely to benefit by examining tumor genetics and biomarkers. This personalized approach could determine whether beta-blockers work better in certain molecular subtypes of colorectal cancer.
Conclusion
While beta-blockers are already widely used and have well-established safety profiles, they should not yet be considered standard colorectal cancer treatments. The current evidence strongly supports further investigation, but carefully designed clinical trials are still essential to confirm whether these affordable medications can genuinely improve survival, reduce recurrence, and become valuable additions to modern colorectal cancer therapy.
The study findings were published in the peer reviewed journal: Cancers.
https://www.mdpi.com/2072-6694/18/15/2507
Read Also:
https://www.thailandmedical.news/articles/cancer
https://www.thailandmedical.news/articles/med-news
Share
Tweet
Share
